Protective effect of mycophenolate mofetil on endothelial function in an aortic allograft model

Transplantation

Volumn 91, Issue 1, 2011, Pages 35-41

  Fréguin Bouilland, Caroline ^a,b   Godin, Michel ^a,b   Bellien, Jeremy ^a,b   Richard, Vincent ^a,b   Remy Jouet, Isabelle ^b   Dautreaux, Brigitte ^b   Henry, Jean Paul ^b   Compagnon, Patricia ^a   Thuillez, Christian ^a,b   Plissonnier, Didier ^a,b   Joannidès, Robinson ^a,b  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE ROUEN   (France)

Author keywords

Calcineurin inhibitor; Endothelial NO synthase; Endothelium; Mycophenolic acid; Nitric oxide

Indexed keywords

ACETYLCHOLINE; CYCLOSPORIN A; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; N(G) NITROARGININE; NITRITE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA GRAFT; ARTICLE; BROWN NORWAY RAT; CELL FUNCTION; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GRAFT REJECTION; IMMUNOSUPPRESSIVE TREATMENT; LEWIS RAT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; THORACIC AORTA; VASOCONSTRICTION;

ANIMALS; AORTA, ABDOMINAL; CYCLIC N-OXIDES; CYCLOSPORINE; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; GRAFT REJECTION; IMMUNOSUPPRESSIVE AGENTS; MALE; MYCOPHENOLIC ACID; NITRIC OXIDE SYNTHASE; NITRITES; NITROARGININE; NITROPRUSSIDE; RATS; RATS, INBRED BN; RATS, INBRED LEW; SPIN LABELS; TREATMENT OUTCOME; VASODILATION;

EID: 78751656807     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181fe12d6     Document Type: Article

References (44)

1. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005;80: S181.
2. Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000;69:2405.
3. Shimizu H, Takahashi M, Takeda S, et al. Conversion from cyclosporine A to mycophenolate mofetil protects recipient kidney and prevents intimal hyperplasia in rat aortic allografts. Transpl Immunol 2004;13:219.
4. Mohacsi PJ, Tüller D, Hulliger B, et al. Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transplant 1997;16:484.
5. Shihab FS, Bennett WM, Yi H, et al. Mycophenolate mofetil ameliorates arteriolopathy and decreases transforming growth factorbeta1 in chronic cyclosporine nephrotoxicity. Am J Transplant 2003;3:1550.
6. Greenstein SM, Sun S, Calderon TM, et al. Mycophenolate mofetil treatment reduces atherosclerosis in the cholesterol-fed rabbit. J Surg Res 2000;91:123.
7. Rodríguez-Iturbe B, Pons H, Quiroz Y, et al. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition. Am J Physiol Renal Physiol 2001;281: F38.
8. Raisanen-Sokolowski A, Vuoristo P, Myllarniemi M, et al. Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts. Transpl Immunol 1995;3:342.
9. Huang Y, Liu Z, Huang H, et al. Effects of mycophenolic acid on endothelial cells. Int Immunopharmacol 2005;5:1029.
10. Haug C, Schmid-Kotsas A, Linder T, et al. The immunosuppressive drug mycophenolic acid reduces endothelin-1 synthesis in endothelial cells and renal epithelial cells. Clin Sci 2002;103: S76.
11. Krötz F, Keller M, Derflinger S, et al. Mycophenolate acid inhibits endothelial NAD (P) H oxidase activity and superoxide formation by a Rac1-dependent mechanism. Hypertension 2007;49:201.
12. Blaheta RA, Nelson K, Oppermann E, et al. Mycophenolate mofetil decreases endothelial prostaglandin E2 in response to allogeneic T cells or cytokines. Transplantation 2000;69:1977.
13. Nickel T, Schlichting CL, Weis M. Drugs modulating endothelial function after transplantation. Transplantation 2006;82: S41.
14. Al-Massarani G, Vacher-Coponat H, Paul P, et al. Impact of immunosuppressive treatment on endothelial biomarkers after kidney transplantation. Am J Transplant 2008;8:2360.
15. Oriji GK, Keiser HR. Nitric oxide in cyclosporine A-induced hypertension: Role of protein kinase C. Am J Hypertens 1999;12:1091.
16. Medina J, Cordier A, Wolf A. Cyclosporine A-induced contraction of isolated rat aortic smooth muscle cells. Life Sci 1997;61:327.
17. Lanese DM, Conger JD. Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest 1993;91:2144.
18. Ramzy D, Rao V, Tumiati LC, et al. Role of endothelin-1 and nitric oxide bioavailability in transplant-related vascular injury: Comparative effects of rapamycinand cyclosporine. Circulation 2006;114: I214.
19. 2+. Circ Res 1994;74:477.
20. Navarro-Antolín J, Lopez-Muñoz MJ, Soria J, et al. Superoxide limits cyclosporine-A-induced formation of peroxynitrite in endothelial cells. Free Radic Biol Med 2002;32:702.
21. Diederich D, Skopec J, Diederich A, et al. Cyclosporine produces endothelial dysfunction by increased production of superoxide. Hypertension 1994;23:957.
22. Cauduro RL, Costa C, Lhulier F, et al. Cyclosporine increases endothelin-1 plasma levels in renal transplant recipients. Transplant Proc 2004;36:880.
23. Plissonnier D, Nochy D, Poncet P, et al. Sequential immunological targeting of chronic experimental arterial allograft. Transplantation 1995;60:414.
24. Savikko J, Kallio EA, Taskinen E, et al. The effect of acute rejection and cyclosporin A-treatment on induction of platelet-derived growth factor and its receptors during the development of chronic rat renal allograft rejection. Transplantation 2002;73:506.
25. Andriambeloson E, Bigaud M, Schraa EO, et al. Endothelial dysfunction and denudation in rat aortic allografts. Arterioscler Thromb Vasc Biol 2001;21:67.
26. Barten MJ, van Gelder T, Gummert JF, et al. Pharmacodynamics of mycophenolate mofetil after heart transplantation: New mechanisms of action and correlations with histologic severity of graft rejection. Am J Transplant 2002;2:719.
27. Cuzzocrea S, McDonald MC, Filipe HM, et al. Effects of tempol, a membrane-permeable radical scavenger, in a rodent model of carrageenan-induced pleurisy. Eur J Pharmacol 2000;390:209.
28. Fréguin-Bouilland C, Alkhatib B, David N, et al. Low molecular weight fucoidan prevents neointimal hyperplasia after aortic allografting. Transplantation 2007;83:1234.
29. Pelletier MM, Kleinbongard P, Ringwood L, et al. The measurement of blood and plasma nitrite by chemiluminescence: Pitfalls and solutions. Free Radic Biol Med 2006;41:541.
30. Kuypers DR, Le Meur Y, Cantarovich M, et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 2010;5:341.
31. Diederich D, Yang Z, Lüscher TF. Chronic cyclosporine therapy impairs endothelium-dependent relaxation in the renal artery of the rat. J Am Soc Nephrol 1992;2:1291.
32. Cristol JP, Vela C, Maggi MF, et al. Oxidative stress and lipid abnormalities in renal transplant recipients with or without chronic rejection. Transplantation 1998;65:1322.
33. Lamas S. Cellular mechanisms of vascular injury mediated by calcineurin inhibitors. Kidney Int 2005;68:898.
34. Förstermann U, Münzel T. Endothelial nitric oxide synthase in vascular disease: From marvel to menace. Circulation 2006;113:1708.
35. Richard V, Hogie M, Clozel M, et al. In vivo evidence of an endothelininduced vasopressor tone after inhibition of nitric oxide synthesis in rats. Circulation 1995;91:771.
36. Weis M, Wildhirt SM, Schulze C, et al. Modulation of coronary vasomotor tone by cytokines in cardiac transplant recipients. Transplantation 1999;68:1263.
37. Jeanmart H, Malo O, Carrier M, et al. Comparative study of cyclosporine and tacrolimus vs newer immunosuppressants mycophenolate mofetil and rapamycin on coronary endothelial function. J Heart Lung Transplant 2002;21:990.
38. Picard N, Prémaud A, Rousseau A, et al. A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. Br J Clin Pharmacol 2006;62:477.
39. Andriambeloson E, Pally C, Hengerer B, et al. Transplantationinduced endothelial dysfunction as studied in rat aorta allografts. Transplantation 2001;72:1881.
40. Weis M, Wildhirt S, Schulze C, et al. Coronary vasomotor dysfunction in the cardiac allograft: Impact of different immunosuppressive regimens. J Cardiovasc Pharmacol 2000;36:776.
41. Trapp A, Weis M. The impact of immunosuppression on endothelial function. J Cardiovasc Pharmacol 2005;45:81.
42. Zoungas S, Kerr PG, Chadban S, et al. Arterial function after successful renal transplantation. Kidney Int 2004;65:1882.
43. Kübrich M, Petrakopoulou P, Kofler S, et al. Impact of coronary endothelial dysfunction on adverse long-term outcome after heart transplantation. Transplantation 2008;85:1580.
44. Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000;57:307.